Cargando…

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To estimate the proportions of patients with relapsing-remitting multiple sclerosis who despite achieving the no evidence of disease activity-3 (NEDA-3) status in the first 2 treatment years experienced relapse-associated worsening (RAW) or progression independent from rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prosperini, Luca, Ruggieri, Serena, Haggiag, Shalom, Tortorella, Carla, Pozzilli, Carlo, Gasperini, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353667/ https://www.ncbi.nlm.nih.gov/pubmed/34373345 http://dx.doi.org/10.1212/NXI.0000000000001059

Ejemplares similares

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
por: Prosperini, Luca, et al.
Publicado: (2022)

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

The added value of spinal cord lesions to disability accrual in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2023)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2014)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review
por: Prosperini, Luca, et al.
Publicado: (2013)

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
por: Pozzilli, Carlo, et al.
Publicado: (2021)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis
por: Kunkl, Martina, et al.
Publicado: (2019)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Predicting the profile of increasing disability in multiple sclerosis
por: Tomassini, Valentina, et al.
Publicado: (2018)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2017)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
por: Gasperini, Claudio, et al.
Publicado: (2012)

Advances in spinal cord imaging in multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis
por: Corsetti, Marta, et al.
Publicado: (2019)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
por: Prosperini, Luca, et al.
Publicado: (2011)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Lesion symptom map of cognitive–postural interference in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2017)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients
por: Sbardella, Emilia, et al.
Publicado: (2013)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
por: Nistri, Riccardo, et al.
Publicado: (2021)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study
por: Palavra, Filipe, et al.
Publicado: (2023)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
por: Newsome, Scott D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8oigtb0qfrff060v7n1d06lhm8